ArticleIndian journal of surgical oncology2025
Identification and Validation of Cuproptosis-Related Signature to Predict Prognosis and Characterize Tumor Immune Infiltration in Kidney Clear Cell Carcinoma.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding cuproptosis and cuproplasia: implications for therapeutic strategies in renal cell carcinoma.Cell death discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuproptosis is a novel form of cell death termed Cu-dependent cytotoxicity. However, the roles of cuproptosis-related genes (CPRGs) in Kidney Clear Cell Carcinoma (KIRC) have not been explored comprehensively. We obtained CPRGs and utilized consensus molecular clustering by "NMF" to stratify KIRC patients in the TCGA cohort. ssGSEA and CIBERSORT algorithms were used to evaluate the relative infiltration levels of immune cell types in a tumor microenvironment (TME). Risk_score based on CPRGs was calculated to predict patients' survival outcomes, and its performance was validated in the E-MTAB-1980 cohort. We identified three clusters with different clinicopathology characteristics. It was found that the cluster with the worst survival rates exhibited a higher enrichment of activated CD4/8 Supplementary Information: The online version contains supplementary material available at 10.1007/s13193-024-02171-x.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.